AMENDMENT TO THE CLAIMS

The present document amends claims 1, 94, 96, 97 and 99, and cancels claims 98, 107, 132-134, 136-138, 142-144, 148 and 149. According to 37 C.F.R. § 1.121(c), after entry of the present amendment, the status of the claims in the case is as follows:

1. (Currently Amended) A composition comprising a first purified antibody, or antigen-binding fragment thereof, and at least a second therapeutic agent; wherein said first antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein ~~at least one of said variable regions is~~ said two variable regions are:

(a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12; ~~or~~ and

(b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.

Claims 2-13 canceled

14. (Previously Presented) The composition of claim 1, wherein said first antibody is an antigen-binding fragment of an antibody.

Claims 15-17 canceled

18. (Previously Presented) The composition of claim 14, wherein said first antibody comprises said antigen-binding fragment of said antibody operatively attached to a human antibody constant region.

Claims 19-22 canceled

23. (Previously Presented) The composition of claim 1, wherein said first antibody is prepared by a process comprising immunizing an animal with activated endothelial cells and selecting from the immunized animal an antibody as defined in claim 1.

Claims 24-50 canceled

51. (Previously Presented) The composition of claim 1, wherein said composition is a pharmaceutically acceptable composition.

52. (Original) The composition of claim 51, wherein said pharmaceutically acceptable composition is formulated for parenteral administration.

Claims 53-93 canceled

94. (Currently Amended) A composition comprising a first purified antibody and at least a second therapeutic agent; wherein said first antibody comprises at least two variable regions that each comprises three CDRs, wherein ~~at least one of said variable regions is~~ said two variable regions are:

(a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12; ~~or~~ and

(b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.

Claim 95 canceled

96. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a biologically effective amount of a first purified antibody, or antigen-binding fragment thereof, and at least a second therapeutic agent; wherein said first antibody or

antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein ~~at least one of said variable regions is~~ said two variable regions are:

(a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12; ~~or~~ and

(b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.

97. (Currently Amended) A kit comprising, in at least a first container, a first purified antibody, or antigen-binding fragment thereof, and at least a second therapeutic agent; wherein said first antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein ~~at least one of said variable regions is~~ said two variable regions are:

(a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ

ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12; ~~or~~ and

(b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.

Claim 98 canceled

99. (Currently Amended) A method for preparing an antibody, comprising immunizing an animal with activated endothelial cells and selecting from the immunized animal an antibody that comprises two variable regions that each comprises three CDRs, wherein ~~at least one of said variable regions is~~ said two variable regions are:

(a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12; ~~or~~ and

(b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid

sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.

Claims 100-105 canceled

106. (Previously Presented) A composition comprising purified monoclonal antibody 3G4 produced by hybridoma ATCC PTA 4545.

Claim 107 canceled

Claims 108-111 canceled

112. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a biologically effective amount of purified monoclonal antibody 3G4 produced by hybridoma ATCC PTA 4545.

Claims 113-116 canceled

117. (Previously Presented) Purified monoclonal antibody 3G4 produced by hybridoma ATCC PTA 4545.

Claims 118-121 canceled

122. (Previously Presented) Hybridoma ATCC PTA 4545.

123. (Previously Presented) A composition comprising purified monoclonal antibody 3G4 produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof.

124. (Previously Presented) The composition of claim 123, wherein said composition comprises said antigen-binding fragment of said monoclonal antibody 3G4 produced by hybridoma ATCC PTA 4545.

125. (Previously Presented) The composition of claim 124, wherein said antigen-binding fragment of said monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, is operatively attached to a human antibody constant region.

126. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a biologically effective amount of purified monoclonal antibody 3G4 produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof.

127. (Previously Presented) The pharmaceutical composition of claim 126, wherein said pharmaceutical composition comprises said antigen-binding fragment of said monoclonal antibody 3G4 produced by hybridoma ATCC PTA 4545.

128. (Previously Presented) The pharmaceutical composition of claim 127, wherein said antigen-binding fragment of said monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, is operatively attached to a human antibody constant region.

129. (Previously Presented) Purified monoclonal antibody 3G4 produced by hybridoma ATCC PTA 4545, or an antigen-binding fragment thereof.

130. (Previously Presented) A hybridoma that produces a monoclonal antibody that comprises two variable regions that each comprises three CDRs, wherein said two variable regions are:

(a) a heavy chain variable region that comprises a variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said variable heavy (VH) CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12; and

(b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said variable light (VL) CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.

131. (Previously Presented) A hybridoma that produces a monoclonal antibody that comprises two variable regions that each comprises three CDRs, wherein at least one of said variable regions is:

(a) a heavy chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:2; or

(b) a light chain variable region from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, which has the amino acid sequence of SEQ ID NO:4.

Claims 132-134 canceled

135. (Previously Presented) The composition of claim 1, wherein said at least a second therapeutic agent is at least a second anti-cancer agent.

Claims 136-138 canceled

139. (Previously Presented) The pharmaceutical composition of claim 96, wherein said first antibody is an antigen-binding fragment of an antibody.

140. (Previously Presented) The pharmaceutical composition of claim 139, wherein said first antibody comprises said antigen-binding region of said antibody operatively attached to a human antibody constant region.

141. (Previously Presented) The pharmaceutical composition of claim 96, wherein said at least a second therapeutic agent is at least a second anti-cancer agent.

Claims 142-144 canceled

145. (Previously Presented) The kit of claim 97, wherein said first antibody is an antigen-binding fragment of an antibody.

146. (Previously Presented) The kit of claim 145, wherein said first antibody comprises said antigen-binding region of said antibody operatively attached to a human antibody constant region.

147. (Previously Presented) The kit of claim 97, wherein said at least a second therapeutic agent is at least a second anti-cancer agent.

Claims 148 and 149 canceled